A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis

British Journal of Rheumatology

Volumn 35, Issue 2, 1996, Pages 150-154

  Ciconelli, R M ^a   Ferraz, M B ^a   Visioni, R A ^a   Oliveira, L M ^a   Atra, E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Combination therapy; Methylprednisolone; Rheumatoid arthritis; Sulphasalazine

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GRIP STRENGTH; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORNING STIFFNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0029967615     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.2.150     Document Type: Article

References (26)

1. Paulus H. The use of combinations of disease modifying anti-rheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990;23:113-20.
2. Healey L, Wilke K. Evaluating combination drug therapy in rheumatoid arthritis. J Rheumatol 1991;18:641-2.
3. Ferraz MB, Visioni RA, Oliveira LM, Ciconelli RM, Atra E. Intravenous methylprednisolone therapy in rheumatoid arthritis. Scand J Rheumatol 1992;21:260-1.
4. Shipley ME, Bacon P, Berry H, Hazleman BL, Sturrock RD, Swenson DR. Pulsed methylprednisolone in active early rheumatoid arthritis: a dose ranging study. Br J Rheumatol 1988;27:211-4.
5. Bax DE, Amos RS. Sulphasalazine: a safe, effective agent for the prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate. Ann Rheum Dis 1985;44:194-8.
6. The Australian Multicentre Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992;19:1672-7.
7. Pinals RS. Sulfasalazine in rheumatic disease. Semin Arthritis Rheum 1988;17:246-59.
8. Arnett FC, Edworthy SM, Bloch DS et al. The American Rheumatism Association 1986 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Ferraz MB, Atra E. Rheumatoid arthritis and the measurement properties of the physical ability dimension of the Stanford Health Assessment Questionnaire. Clin Exp Rheumatol 1989;7:341-4.
10. Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis. Ann Rheum Dis 1993;52:711-5.
11. Hear D, Solvkyaer M, Unger B, Rasmussen KJE, Christensen L, Hansen TM. A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. Scand J Rheumatol 1993;22:113-8.
12. Situnayake RD, McConkey B. Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: The effects of disease duration on treatment response. J Rheumatol 1990;17:1268-73.
13. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis - no benefit of addition of hydroxychloroquine to patients with suboptimal response to intramuscular gold therapy. J Rheumatol 1993;20:645-9.
14. Jones E, Jones JV, Woodbury JFL. Response to sulfasalazine in rheumatoid arthritis: life table analysis of 5-year follow-up. J Rheumatol 1991;18:195-8.
15. Samanta A, Welb C, Grindulis KA, Fleming J, Sheldon PJ. Sulphasalazine therapy in rheumatoid arthritis: qualitative changes in lymphocytes and correlation with clinical response. J Rheumatol 1992;31:259-63.
16. Garrett R, Paulus H. Complications of intravenous methylprednisolone pulse therapy in rheumatoid arthritis. Arthritis Rheum 1980;23:677.
17. Hansen TM, Dickness E, Jans H, Hansen TI, IngemannNielsen M, Lorenzen IB. Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis. Ann Rheum Dis 1987;46:290-5.
18. Sternberg EM, Hill JM, Chrousos GP et al. Inflammatory mediator induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis susceptible Lewis rats. Proc Natl Acad Sci USA 1989;86:2374-8.
19. Chikanza IC, Petrou P, Kingsley G, Chrousos G, Panayi GS. Abnormal cortisol response to surgery in rheumatoid arthritis. Clin Rheumatol 1992;11,1:102.
20. Choy EHS, Kingsley GH, Corkill MM, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol 1993;32:734-9.
21. Gough A, Sheeran T, Arthur V, Panayi G, Emery P. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study. Scand J Rheumatol 1994;23:46-8.
22. Gran JT, Myklebust G. Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids. Scand J Rheumatol 1993;22:229-32.
23. Kitas GD, Waterhouse L, Bacon PA. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992;21:220-5.
24. Wiynands MJH, Van'Thof MA, Van de Putte LBA, Van Riel PLCM. Rheumatoid arthritis: A risk factor for sulphasalazine toxicity? A meta-analysis. Br J Rheumatol 1993;32:313-8.
25. Amor RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 year. Br Med J 1986;293:420-3.
26. Farr M, Johnson A, Jones PJ, Popert AJ, Bacon PA. Sulphasalazine - A rapidly acting drug in rheumatoid arthritis. A comparative study with penicillamine [Abstract]. Arthritis Rheum 1994;37(suppl.):256.